ficerafusp alfa

·Code: BCA101

ficerafusp alfa: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.

Development Pipeline (1)

Company	Phase	Indication
Bicara Therapeutics Inc. (BCAX)	Phase 2/Phase 3	Metastatic Head and Neck Squamous Cell Carcinoma

Clinical Trials (1)

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06788990·Phase 2/Phase 3·BCAX

Recruiting

Frequently asked questions

Who is developing ficerafusp alfa?

ficerafusp alfa is being developed by Bicara Therapeutics Inc..

How many clinical trials involve ficerafusp alfa?

BioSniper tracks 1 clinical trial involving ficerafusp alfa.

Get deeper analysis on ficerafusp alfa

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis